BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley(Roswell Park Comprehensive Cancer Center), David M. Hyman(Memorial Sloan Kettering Cancer Center), Ian Chau(Royal Marsden NHS Foundation Trust), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Franck Bielle(Centre National de la Recherche Scientifique), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Florence Joly(Centre François Baclesse), Vivek Subbiah(Sarah Cannon), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Noopur Raje(Massachusetts General Hospital), Ralf‐Dieter Hofheinz(University of Mannheim), Martina Makrutzki(Roche (Switzerland)), Bethany Pitcher(Roche (Canada)), Mehdi Touat(Broad Institute), Antoine Hollebecque(Institut Gustave Roussy), Vicki L. Keedy(Vanderbilt University Medical Center), A. Craig Lockhart(Roswell Park Comprehensive Cancer Center), Jürgen Wolf(University of Cologne), José Baselga(Novartis (Switzerland)), Todd Riehl, Lisa M. DeAngelis(Memorial Sloan Kettering Cancer Center)
Cited by 330
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k